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Introduction: Pathologic complete response (pCR) with neoadju-
vant chemotherapy is associated with improved survival in many 
solid tumors. We evaluated pCR rate of cisplatin with pemetrexed in 
non–small-cell lung cancer.
Methods: Patients with stages IB to IIIA non–small-cell lung can-
cer, Eastern Cooperative Oncology Group performance status 0 to 1 
were enrolled in this single-arm phase II trial using two-stage design 
with 90% power to detect pCR rate of more than or equal to 10%. 
Pretreatment mediastinal lymph node biopsy was required. Patients 
received three cycles of cisplatin 75 mg/m2 with pemetrexed 500 mg/
m2 (day 1 every 21 days) preoperatively and additional two cycles 
within 60 to 80 days after surgery. The primary end point was pCR. 
Polymorphisms in FPGS, GGH, SLC19A1, and TYMS genes were 
correlated with treatment outcomes.
Results: Thirty-eight patients were enrolled, with median age of 62.5 
years. Preoperatively, 26% had squamous histology, and 34% had 
biopsy-proven N2 involvement. R0 resection was achieved in 94% 
of the 34 patients who underwent surgery, and 54% had documented 
N2 clearance. There was no pCR seen. Median disease-free survival 
(DFS) and overall survival of these patients have not yet been reached 
in contrast to median of 13.8 and 24.2 months, respectively, in patients 
with persistent N2 disease (p = 0.3241 and p = 0.1022, respectively). 
There was a statistically significant association between DFS and 
postoperative tumor, node, metastasis stage (p = 0.0429), SLC19A1 
rs3788189 TT genotype (p = 0.0821), and viable tumor defined as less 
than or equal to 10% of resected specimen (p = 0.026).
Conclusion: The primary end point was not met. Patients with N2 clear-
ance, less than or equal to 10% viable tumor in the resected specimen, 
and SLC19A1 rs3788189 TT genotype have favorable DFS outcomes.
Key Words: Neoadjuvant chemotherapy, Non–small-cell lung can-
cer, Pemetrexed, Cisplatin, Pharmacogenetics.
(J Thorac Oncol. 2014;9: 222–230)
Lung cancer is the leading cause of cancer deaths in the United States, with estimated 228,080 new cases and 159,480 
deaths in 2013.1 Although surgery is curative for resectable 
stages of non–small-cell lung cancer (NSCLC), 5-year survival 
estimates are inferior to breast, colon, and prostate cancer. As 
distant relapse is the predominant reason for treatment failure 
upon long-term follow-up, this has led to the investigation of the 
role of systemic therapy in the perioperative setting. Delivering 
chemotherapy preoperatively offers the potential for control 
of micrometastatic disease and tumor debulking to reduce the 
extent of planned surgery. Moreover, a few randomized studies 
in the 1990s demonstrated survival improvements with preop-
erative chemotherapy compared with surgery alone.2–4 In con-
trast to the lack of survival benefit for patients with pathologic 
complete response (pCR) after receiving preoperative radiation 
in NSCLC,5,6 pCR seen after preoperative chemotherapy is asso-
ciated with improved survival outcomes and is a major end point 
in the evaluation of preoperative chemotherapy trials.7–9
In 2003–2004, several large phase III trials confirmed 
a significant benefit from adjuvant chemotherapy in the treat-
ment of early-stage NSCLC.10–13 In addition, the meta-analysis 
“Lung Adjuvant Cisplatin Evaluation” confirmed a survival 
benefit from cisplatin-based adjuvant chemotherapy in lung 
cancer.14 It is important to note, however, that sustained sur-
vival benefit is not all encompassing and dependent on the 
chemotherapy regimen utilized.15
Based on the high systemic failure rates even in com-
pletely resected NSCLC, we designed a phase II trial evaluating 
cisplatin in combination with pemetrexed administered neoad-
juvantly followed by adjuvant treatment for surgical candidates 
with stage IB to IIIA NSCLC. Pemetrexed is metabolized by 
the folate pathway enzymes, including folylpolyglutamate 
synthetase (FPGS), γ-glutamyl hydrolase, solute carrier 19A1 
(SLC19A1), and thymidylate synthase (TYMS). Polymorphisms 
in the genes encoding these proteins have been associated with 
variable treatment outcomes16–21; therefore, we investigated the 
correlation between single-nucleotide polymorphisms (SNPs) in 
these four genes and the clinical outcomes for this study.
PATIENTS AND METHODS
Eligibility
Eligible patients must have had newly diagnosed 
NSCLC, disease stage T2N0M0, T1-3N1M0, or T1-3N2M0 
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(as defined by 6th edition of TNM classification) and deemed 
to be potential surgical candidates by a thoracic surgeon. 
Patients were required to have adequate bone marrow, hepatic, 
and renal function (creatinine clearance ≥45 ml/min based on 
the Cockcroft and Gault formula) and Eastern Cooperative 
Oncology Group performance status 0 to 1. Patients with dis-
tant metastasis, biopsy-proven N3 nodal involvement, malig-
nant pleural effusion, or a history of other malignancy within 
the preceding 2 years (except nonmelanoma skin cancer and 
cervical carcinoma in situ) were excluded from this trial. 
Subsequent to the findings released in 2008–2009 regarding 
inferior outcomes with pemetrexed treatment among patients 
with squamous cell NSCLC,22,23 patients with predominant 
squamous cell carcinoma histology were excluded starting 
January 2010. The trial was approved by the Roswell Park 
Cancer Institute Institutional Review Board, and each patient 
provided written informed consent before starting protocol-
related activities.
Study Treatment and Procedures
All patients underwent chest and abdomen computed 
tomography (CT) scan for tumor measurement, positron emis-
sion tomography (PET) scan, electrocardiography, and pul-
monary function tests for screening at baseline. Mediastinal 
lymph node evaluation was performed with either medi-
astinoscopy or endobronchial ultrasound-guided biopsy of 
mediastinal lymph nodes before initiating protocol treatment. 
Patients were given vitamin B12 (repeated once every 9 wk) 
and folic acid supplementation at least 1 week before cycle 1 
day 1 of chemotherapy. Cisplatin 75 mg/m2 and pemetrexed 
500 mg/m2 were administered on day 1 of each 21-day cycle 
along with standard hydration and antiemetic regimens. They 
were evaluated weekly using the National Cancer Institute 
Common Toxicity Criteria (CTC) version 3.0 to assess sever-
ity of adverse effects. After three cycles of chemotherapy, CT 
chest and abdomen and PET scans were repeated. Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria version 
1.0 was used for evaluation of objective response rate (ORR).
Patients with complete response, partial response, or 
stable disease by CT and PET scans underwent surgery, no 
earlier than 28 days after the last dose of chemotherapy but 
between days 70 to 90 from the start of treatment. Patients 
underwent either standard thoracotomy or video-assisted tho-
racoscopic surgery for a lobectomy, bilobectomy, or pneumo-
nectomy with mediastinal lymph node dissection as described 
by Martini.24
Patients deemed to have unresectable disease or disease 
progression were subsequently removed from study treatment 
and followed every 6 months until the time of death. Patients 
who had R0 resection, with an Eastern Cooperative Oncology 
Group performance status of 0 to 1, received two additional 
cycles of cisplatin with pemetrexed within 60 days after sur-
gery provided there were no uncontrolled intercurrent ill-
nesses. Patients with incomplete resections, positive margins 
or those found to have multistation N2 disease or extracapsu-
lar lymph nodal involvement could receive adjuvant radiation 
following adjuvant chemotherapy according to standard of 
care. Follow-up visits with surveillance imaging studies were 
performed every 3 months for 2 years, then every 6 months for 
3 years, and annually thereafter.
Study Design
A two-stage phase II study based on Simon design was 
conducted to assess the efficacy of this regimen. The primary 
end point was pCR, which was defined as surgical pathology 
specimen free of all gross and microscopic evidence of viable 
tumor. Patients who consented to the study but did not receive 
any chemotherapy were excluded from the analysis. Patients 
were considered evaluable for determination of primary end 
point if they received at least one cycle of preoperative che-
motherapy. For the purpose of the decision rule, in addition 
to the pCR definition, the following were considered equiva-
lent to not having a pCR: interval development of radiologic 
findings that contraindicate surgery, surgery being aborted 
according to the best judgment of the surgeon, R1 or R2 resec-
tion. For descriptive purposes only, overall and disease-free 
survival (DFS) estimates were computed using the Kaplan–
Meier method. Survival outcomes were calculated from the 
date of administration of first chemotherapy cycle.
The trial was designed to test the null hypothesis that the 
probability of pCR was less than 2% against the alternative 
more than 10%, using a sample size of 52 with a significance 
level of 0.08 and power of 90%. To test this hypothesis, 38 
patients were to be accrued during the first stage. Accrual was 
completed at this stage if either zero or at least three pCRs 
were documented and the regimen considered inactive or 
active, respectively. If at least two pCRs were observed, study 
would accrue an additional 14 patients in the second stage. 
If no additional pCRs were noted, regimen would be consid-
ered inactive. If there were at least three documented pCRs 
among the 58 patients accrued, the regimen would be consid-
ered active.
Correlative Pharmacogenetic Studies
Ten milliliters of blood was drawn into ethylenediami-
netetraacetic acid tubes at baseline and DNA extracted and 
preserved until the end of the study for genotyping. SNP 
information for FPGS, γ-glutamyl hydrolase, SLC19A1, and 
TYMS were acquired as previously described and had also 
been identified in preliminary studies as potentially prognos-
tic or predictive for treatment outcomes with pemetrexed.19–21 
Genotyping of the SNPs has been described elsewhere.20
Statistical Analysis
As the 7th edition of TNM staging was proposed and 
published in 2007, the data obtained initially using the 6th 
edition were reclassified as appropriate. Descriptive sta-
tistics such as frequencies and relative frequencies were 
computed for categorical variables. Numeric variables were 
summarized using simple descriptive statistics, such as the 
mean, SD, median, and range. Fisher’s exact test was used to 
study the association between categorical variables. Adverse 
events were tabulated and reported using the CTC version 
3.0. The Wilcoxon ranked sum test was used to compare 
the groups with regard to numeric variables. The estimated 
overall survival (OS) and DFS distributions were obtained 
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using the Kaplan–Meier method. Using this distributional 
estimate, summary descriptive statistics such as the median 
survival and a 95% confidence interval of the median sur-
vival were obtained. Statistical assessment of observed dif-
ferences in the survival distributions of different groups 
of interest was done using the log-rank test. The Cox pro-
portional hazards model was used to assess the association 
between numeric variables and the survival. Exact 95% 
confidence interval using the Clopper–Pearson method 
was obtained for the ORR. SNP analysis was performed 
using dominant model, that is, the homozygous alleles with 
lower prevalence were combined with the heterozygous 
alleles versus the homozygous alleles with higher preva-
lence. Adjusted p values were also provided using the linear 
step-up method of Benjamini and Hochberg. A 0.05 nomi-
nal significance level was used in all testing. All statistical 
analyses were done using SAS (version 9.3; SAS Institute, 
Cary, NC).
RESULTS
Patients
From September 2005 to January 2011, 38 patients 
were accrued. Baseline patient characteristics are summarized 
in Table 1. Male to female ratio was 1:1. Adenocarcinoma 
was the most frequent histology (55%). Thirty-two patients 
had already been accrued before the protocol amendment 
excluding squamous cell histology by January 2010. Nineteen 
patients (50%) had clinical stage IIIA disease. Thirteen 
patients had biopsy-proven N2 nodal involvement before 
treatment. Due to logistical challenges (such as PET scan per-
formed at another institution), baseline and postchemotherapy 
PET scan maximal standardized uptake values (SUV) were 
available for analysis in 16 patients only.
Systemic Treatment and Toxicities
All patients received at least one cycle of chemother-
apy. Thirty-five patients (92%) received all three induction 
treatment cycles. A median of four cycles of chemotherapy 
(including adjuvant) was administered. Eighteen patients 
(47%) received five cycles without dose reductions or dose 
delays. One patient had both dose reduction and dose delay 
(3%). Among three patients who received less than three 
cycles of neoadjuvant chemotherapy, two patients discontin-
ued therapy due to toxicity (one for CTC grade 3 drug fever 
and the other for CTC grade 3 sensory neuropathy) and the 
third patient was taken off protocol due to interval disease 
progression. CTC more than or equal to grade 3 nonhema-
tologic adverse events (<10%) included arterial thrombosis, 
bronchopleural fistula, empyema, hyperglycemia, fatigue, 
and tinnitus. There were no CTC grade 5 events attributable 
to study treatment. Table 2 lists frequency of relevant toxici-
ties encountered in this study.
Treatment Response according 
to Imaging Modality
The ORR for all 38 patients was 29% (11 partial 
responses). Disease progression was noted in 11% (n = 4). 
Stable disease was noted in 60% (n = 23). There was no radio-
logic complete response noted. There was no association 
between ORR with histologic type, baseline, or postchemo-
therapy PET scan SUV value or absolute change of PET scan 
SUV value before and after chemotherapy. Percent change 
of maximal SUV between baseline and postchemotherapy 
PET scan correlated with ORR (p = 0.0259), with median 
percent SUV reduction among responders of 68.5% (range, 
57.1%–78.7% reduction) compared with median of 29.5% 
reduction among nonresponders (ranging between increase in 
percent SUV of 51.5% to reduction of 92.4%). Nevertheless, 
as described previously, complete data were only available in 
16 of 38 patients.
Surgical Treatment, Morbidity, and Mortality
Of 38 patients, 34 patients (89%) underwent thora-
cotomy. Four patients did not undergo surgery due to the fol-
lowing reasons: Three patients had disease progression by 
RECIST criteria which precluded surgery. One patient who 
had stable disease radiographically after induction chemo-
therapy had hypoxia due to difficult intubation process and 
surgery was aborted.
Among the 34 patients who underwent were able to 
undergo surgery, 32 patients (94%) had R0 resection. Median 
number of resected lymph nodes (including the ones sampled 
through mediastinoscopy before starting neoadjuvant che-
motherapy) was 14.5 (range, 5–42). Complete resection was 
achieved in 23 patients (67.6%) by thoracoscopic approach. 
Nine patients (26.5%) underwent conversion to standard tho-
racotomy after initial video assisted thoracoscopic surgery 
(VATS) approach, whereas two patients underwent standard 
thoracotomy upfront (5.9%). Six patients (17.6%) underwent 
pneumonectomy, four of which were completed thoracoscopi-
cally. All remaining resections were lobectomies with excep-
tions for the two R2 resection cases as described below.
TABLE 1.  Baseline Characteristics of 38 Patients Enrolled
Variable Results (%)
Age
 Median 62.5
 Range 39–75
Sex
 Male 19 (50%)
Performance status
 0 28 (74%)
 1 10 (26%)
Histology
 Squamous cell 10 (26%)
 Adenocarcinoma 21 (55%)
 Large-cell neuroendocrine 3 (8%)
 Poorly differentiated, not otherwise specified 4 (11%)
Clinical stage (preoperative)
 IB 5 (13%)
 IIA 7 (18.5%)
 IIB 7 (18.5%)
 IIIA 19 (50%)
Biopsy-proven N2 nodal involvement 
before initiation of chemotherapy
13 (34%)
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One of the two patients classified to have R2 resection 
had disease progression by RECIST due to interval develop-
ment of separate ipsilateral left upper lung nodules despite 
mild reduction in size of the primary left lower lobe hilar 
mass. This patient underwent planned VATS wedge excision 
of one of the new nodules which was confirmed intraoper-
atively to be malignant (T4 using the current 7th edition of 
TNM staging). Further surgery was not pursued. This patient 
was classified as having R2 resection and received a differ-
ent chemotherapy regimen subsequently. The second patient 
with R2 resection had stable disease by RECIST on the post-
chemotherapy imaging studies but underwent VATS explor-
atory thoracoscopy only as there was a pleural nodule found 
intraoperatively separate from the tumor mass. Frozen sec-
tions of this nodule and another N2 node documented pres-
ence of malignant cells.
Perioperative mortality rate in this small cohort was 0%. 
Four patients required reoperation or bronchoscopic evalua-
tion within 30 days for the following reasons: One patient had 
persistent air leak requiring suture repair of bronchopleural 
fistula and mechanical pleurodesis 8 days after initial VATS 
left upper lobectomy. Another patient required emergent 
thoracoscopy for evacuation of hematoma 3 days after sur-
gery. A third patient underwent decortication and drainage of 
empyema 19 days after the preceding thoracotomy. The last 
patient had mucus plugging causing lobar collapse for which 
the patient underwent bronchoscopic evaluation and suction-
ing. A total of four patients required rehospitalization within 
30 days for the following reasons: postoperative ileus 2 days after 
initial hospital discharge (postoperative day 4), bilateral bron-
chopneumonia 2 days after initial hospital discharge (postop-
erative day 4), symptomatic worsening dyspnea 10 days after 
hospital discharge (postoperative day 12) requiring inpatient 
pulmonary toilet, and one patient with empyema who was 
readmitted to the hospital (postoperative day 6) 1 day after 
initial hospital discharge who then underwent decortication as 
described above.
Pathologic Assessment
Pathologic response of the lung cancer to induction che-
motherapy was evaluated on standard hematoxylin–eosin his-
topathology on the 33 patients who underwent at least a wedge 
resection of a lung tumor specimen. Proportion of viable tumor, 
necrosis, and fibrosis/inflammation were each determined in 
increments of 5% for each specimen (composite total of 100%). 
There was no pCR noted during the first stage and thus accrual 
to the second stage was not pursued. Percent viable tumor 
ranged from 5% to 100%, with median of 70% viable residual 
tumor. Eight patients, of whom five had partial response (PR) 
by RECIST criteria, had less than or equal to 10% viable malig-
nant cells in the resected specimen (four patients with 5% and 
four patients with 10% viable tumor remaining). Percentage 
necrosis ranged from 0% to 30%, with a median of 10% necro-
sis (0% in 11 patients, 5% in two patients, 10% in six patients, 
15% in one patient, 20% in nine patients, and 30% in four 
patients). Percentage of fibrosis/inflammation ranged from 0% 
to 95%, with a median of 20% fibrosis/inflammation (<50% in 
21 patients and ≥50% in 12 patients).
Seventeen patients had suspected N2 nodal involve-
ment based on CT and/or PET criteria before initiation of 
chemotherapy. Thirteen patients had biopsy-proven N2 
nodal involvement before chemotherapy. Eleven of these 13 
patients underwent thoracotomy, and N2 nodes were positive 
in four patients and negative in seven patients. One patient 
who had pretreatment PET-positive paratracheal adenopathy 
that was negative by mediastinoscopy performed before start-
ing chemotherapy and clinically negative N2 involvement by 
CT/PET criteria after three cycles of chemotherapy before 
TABLE 2.  Adverse Events Encountered per Patient Attributed to Chemotherapy
Adverse Event
All CTC Grades CTC Grade 3 CTC Grade 4
n % n % n %
Fatigue 22 57.9 3 7.9 0 0
Nausea 22 57.9 0 0 0 0
Anemia 19 50 1 2.6 0 0
Diarrhea 12 31.6 0 0 0 0
Tinnitus 10 26.3 1 2.6 0 0
Neutropenia 10 26.3 2 5.3 0 0
Vomiting 7 18.4 0 0 0 0
Sensory neuropathy 6 15.8 1 2.6 0 0
Elevated transaminase 5 13.2 0 0 0 0
Thrombocytopenia 5 13.2 0 0 0 0
Hyperglycemia 4 10.5 2 5.3 0 0
Constipation 3 7.9 0 0 0 0
Arterial thromboembolism 1 2.6 1 2.6 0 0
Empyema 1 2.6 1 2.6 0 0
Bronchopleural fistula 1 2.6 1 2.6 0 0
Febrile neutropenia 0 0 0 0 0 0
CTC, Common Toxicity Criteria.
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surgery was found to have microscopic involvement of three 
resected subcarinal lymph nodes in the permanent hema-
toxylin–eosin sections after lobectomy. Thus, a total of five 
patients had N2 lymph node involvement documented in 
their postchemotherapy surgical specimen. Two of these five 
patients received postoperative radiation following additional 
chemotherapy within 4 months after surgery.
Survival
As of November 30, 2012, median follow-up was 
37.1 months (range, 1.5–78 mo). Disease progression had 
occurred in 20 patients (52.6%). Documented relapses were 
distant except in two patients: one patient had biopsy-proven 
mediastinal lymph node involvement as the solitary site of 
relapse 14 months after initial surgery. He received concurrent 
chemoradiation but subsequently died 28 months thereafter 
from cardiac complications. The second occurred in the patient 
who underwent definitive chemoradiation after surgery was 
aborted due to hypoxia during intubation as described above. 
Surveillance imaging showed locoregional disease progres-
sion 16 months after completing chemoradiotherapy. He opted 
for best supportive care only with no further imaging stud-
ies and died 15 months later. Figure 1 shows the OS curve of 
clinical tumor, node, metastasis grouping preoperatively in the 
34 patients who underwent surgery. Figures 2 and 3 show the 
Kaplan–Meier DFS and OS curves according to postoperative 
FIGURE 1.  Overall survival Kaplan–Meier 
curve according to preoperative stage 
(n = 34). CI, confidence interval.
FIGURE 2.  Disease-free survival Kaplan–
Meier curve according to postoperative 
stage (n = 34). CI, confidence interval.
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pathologic stage. For the entire cohort, median DFS was 24.5 
months (95% CI, 15.4, not reached), with 2-year and 5-year 
DFS rate of 54.8% (95% CI, 37.7%, 69%) and 46% (95% 
CI, 29.4%, 61.1%), respectively. Median OS for the entire 
cohort, as shown in Figure 4, has not been reached (95% CI, 
35.9, not reached), with 2-year and 5-year OS rate of 81% 
(95% CI, 64.2%, 90.5%) and 55.6% (95% CI, 37%, 70.6%), 
respectively.
Variables Associated with Survival Outcomes
Among patients who underwent surgery, postopera-
tive stage was the most important variable associated with 
DFS (p = 0.0429). Nevertheless, this was not significantly 
associated with OS (p = 0.2084). Figures 2 and 3 show the 
Kaplan–Meier curves demonstrating DFS and OS accord-
ing to postoperative stage. Among the patients with N2 nodal 
clearance, median DFS and OS of these patients have not yet 
been reached in contrast to 13.8 and 24.2 months, respectively, 
in patients with persistent N2 disease. The difference is, how-
ever, not statistically significant (p = 0.3241 and p = 0.1022, 
respectively).
Other parameters, such as preoperative stage, objective 
response, histology, sex, and smoking status, were not associ-
ated with either OS or DFS. Although a trend toward improved 
DFS and OS was observed for those with an objective radio-
logic response, this difference was not statistically significant 
FIGURE 3.  Overall survival Kaplan–Meier 
curves according to postoperative stage 
(n = 34). CI, confidence interval.
FIGURE 4.  Kaplan–Meier curve for overall 
survival in the entire cohort (n = 38). CI, 
confidence interval.
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(p = 0.3414 and p = 0.4136). Pathologic response as defined 
by the proportion of viable tumor less than or equal to 10% 
in the resected specimen was associated with an improved 
DFS (p = 0.0223) but not OS. When analyzed as continu-
ous variables, percentages of viable tumor or fibrosis/inflam-
mation were associated with DFS (hazard ratio, 1.031; 95% 
CI, 1.002–1.039; p = 0.026 and hazard ratio, 0.977; 95% CI, 
0.956–0.997; p = 0.0282, respectively) but not OS. Percentage 
of necrosis was associated with neither DFS nor OS. Data for 
DFS are summarized in Table 3.
Comparing the OS of patients with complete resec-
tion (n = 32) with those who had incomplete or no resection 
(n = 6), we found 2-year and 5-year survival rates of 87.2% 
(95% CI, 69.4%–95%) and 61.3% (95% CI, 40.7%–76.6%) 
for the former and 50% (95% CI, 11.1%–80.4%) and 25% 
(95% CI, 1.2%–64.6%) for the latter patients, respectively. 
The median OS time for patients with complete resection has 
not been reached (95% CI, 37% to not reached), and it was 
27.7 months (95% CI, 1.5 mo, not reached) for those with 
incomplete/no resection (p = 0.0136).
Pharmacogenetics
Twenty-one tagSNPs generated from the four genes with 
minor allele frequency more than 5% were successfully geno-
typed and were in Hardy–Weinberg equilibrium. Genotypes 
observed in less than 5% patients were regrouped, and if the 
regrouped frequency was less than or equal to 10%, the SNP 
was excluded from the analyses with the clinical outcomes. 
The SNPs were analyzed for their interaction with ORR, DFS, 
and OS. Three SNPs correlated with OS and DFS. At the time 
of analysis, the median survival was significantly decreased 
for patients with the FPGS rs10987742 variant TT genotype 
(OS: p = 0.0009; DFS: p = 0.0216) and TYMS rs2853533 vari-
ant CC genotype (OS: p = 0.0005) even though the median OS 
for FPGS rs10987742 CC and TYMS rs2853533 GG genotypes 
has not been reached. SLC19A1 rs3788189 G>T polymor-
phism, located in the intronic region of the folate transporter 
gene, though not statistically significant, was associated with 
DFS: with the median DFS of 21.6 months for the homozy-
gous GG genotype versus a median DFS that has not yet been 
reached for the homozygous TT genotype (p = 0.0821). The 
AA genotype for SLC19A1 rs2838958 correlated with ORR 
(trend of association p value = 0.072). Supplementary Tables 
1 and 2 (Supplementary Digital Content 1, http://links.lww.
com/JTO/A519) list the individual association results for gen-
otypes with ORR, DFS, and OS.
DISCUSSION
Our study is the first phase II study to complete the eval-
uation of pemetrexed in combination with cisplatin as preop-
erative chemotherapy followed by adjuvant treatment for stage 
IB to IIIA NSCLC. Another single-arm phase II study using 
the same regimen neoadjuvantly for a similar patient popu-
lation in Spain (NCT002592850) was initiated in December 
2005 and projected to enroll 44 patients. This study was, how-
ever, terminated in 2008 due to poor accrual and survival out-
comes measures were thus not analyzed in the 10 patients who 
were enrolled. There were five partial responses, one patient 
with disease progression with a total of seven patients who 
underwent surgery.25 A randomized European Organization for 
Research and Treatment of Cancer (EORTC) phase II study of 
pemetrexed and cisplatin as either induction or adjuvant che-
motherapy in approximately 130 patients with stage IB to II 
NSCLC was first launched in October 2006 (EORTC-08051, 
TABLE 3.  Log-Rank Test for Disease-Free Survival in the 34 Patients Who Underwent Surgery
Variable Level Total Number Failed Number Censored Median Survival (95% CI) p
Response No 23 12 11 24.5 (14.7, NR) 0.3414
Yes 11 4 7 NR (14.7, NR)
Histology Nonsquamous 25 14 11 24.5 (15.4, NR) 0.1159
Squamous 9 2 7 NR (2.3, NR)
Preoperative stage I 5 1 4 NR (34.5, NR) 0.1762
II 14 9 5 22.4 (7, NR)
III 15 6 9 NR (12.2, NR)
Postoperative stage I 16 4 12 NR (34.5, NR) 0.0429
II 10 7 3 22.9 (7, NR)
III 8 5 3 15 (2.3, NR)
Sex Female 16 8 8 NR (11.5, NR) 0.6719
Male 18 8 10 NR (15.4, NR)
Smoking No 2 1 1 NR (3.2, NR) 0.5177
Yes 32 15 17 NR (21.4, NR)
Viable tumora ≤10% 8 1 7 NR (34.5, NR) 0.0223
>10% 25 15 10 23.1 (14.7, NR)
Resection Complete 32 15 17 NR (21.4, NR) 0.6882
Incomplete 2 1 1 NR (2.3, NR)
aAssessed in 33 of 34 patients who underwent at least a wedge resection of the lung mass. Not included in the analysis was the specimen from one patient who had exploratory 
thoracoscopy and mediastinal sampling only. Further operation was discontinued when a pleural nodule and a mediastinal lymph node showed presence of malignant cells.
CI, confidence interval; NR, not reached.
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NCT00389688). This study also closed in 2008 because of 
poor recruitment.26 Although the primary end point was not 
met, we were able to show that preoperative chemotherapy 
using this regimen did not result in increased postoperative 
mortality, similar to what has been reported in larger random-
ized studies.27–30 Nevertheless, it is to be emphasized that the 
standard of care for patients with early-stage NSCLC is sur-
gery upfront followed by adjuvant chemotherapy as indicated.
The pCR rate seen in our study is similar to what has 
been published for cisplatin-based induction chemotherapy 
regimens (without the combination of preoperative radiation), 
ranging typically from 0% to 10%,27,31 though some studies 
report pCR rates of 15% to 19%.32,33 Although this variability 
is undoubtedly in part due to heterogeneity of NSCLC and 
type of regimen used, there is lack of uniform or standard defi-
nition of pCR across different studies, with some studies indi-
cating more than or equal to 95% necrosis/sclerosis as pCR33,34 
as opposed to the implied definition of complete necrosis or 
absence of any viable tumor cells. Thus, the presumption that 
pCR meant a complete absence of cancer cells cannot be taken 
for granted across studies. In addition, there is a lack of associ-
ation between histologic type and response rate. Our study did 
not reveal an inferior outcome among patients with squamous 
histology. Although this may be related to the small sample 
size, new findings suggest that gene expression profiling may 
further refine the ability to identify subset of squamous cell 
carcinoma who may respond to pemetrexed treatment.35
This study is limited by the small number of patients 
accrued and the lack of a suitable control arm. Although 
the primary end point was not reached, the results from this 
study provide further evidence of the strong prognostic factor 
associated with mediastinal downstaging. A phase II study is 
currently ongoing, with planned enrollment of 33 patients to 
evaluate the efficacy of cisplatin and pemetrexed as preop-
erative chemotherapy for nonsquamous NSCLC patients with 
N2 nodal involvement (NCT 01165021). Our results support 
current observations that surgery for selected patients with 
known N2 disease may result in long-term survival provided 
there is clear demonstration of pathologic clearance of N2 
nodal disease.33,36 Observations from other retrospective 
studies suggest that surgery after chemotherapy could still be 
effective even in patients with persistent N2 disease, provided 
clinical response was demonstrated and complete resection 
can be achieved.31,37,38 Polymorphisms in the folate transporter 
SLC19A1 have been shown to be associated with survival 
outcomes in NSCLC patients treated with pemetrexed-based 
regimens.19,20,39 This study revealed that SLC19A1 rs3788189 
polymorphism which was associated with OS in a previous 
study19 was also associated with DFS in this study although 
it did not reach statistical significance. SNPs in FPGS and 
TYMS were also found to be associated with inferior OS and/
or DFS. Although the functional implication of these poly-
morphisms is yet to be characterized, in some cases such as 
the TYMS rs2853533 SNP which was associated with inferior 
OS in this study, it has been linked to 5-FU cytotoxicity.40
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